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A sequence of novel compounds pyrazolopyridine have been prepared by a general synthetic method. Due to high efficiency 
and selectivity, anticancer agents consisting of combined molecules have gained great interests. The IC50 values have been 
determined against cell line U937, the results obtained indicate the potential effects against cancer cell line. The cell potency of 
cell line is best for compounds 4a IC50 = 62.5 μM, 5b IC50 = 62.5 μM,4b IC50 = 31.2 μM, 4e IC50 = 31.2 μM), selectivity 
and in vivo. Further, the molecular docking studies indicate that substituted pyrazolo[4,3-c]pyridine derivatives show good 
anticancer activity in the medicinal field. The ease of synthesis and the significant biological activities make these 
compounds potential new frameworks for progress of cancer therapeutics. Compound 4f shows anticancer effect in cancer 
cell lines and in vivo that corresponds with antitumor activity in an AML cancer type. For the molecular docking with the 
ligands, the RMSD value has been calculated, the protein with the least RMSD is found to be 5KTU screening with 20  
small molecules. 
Keywords: Pyrazolopyridine, anti-cancer, bromodomains, molecular dynamics 
Worldwide, cancer is the most commonly diagnosed 
malignancy leading to deaths1. Chemical modification 
of biologically active compounds of natural origin is 
one of the most efficient approaches in drug 
development. Pyrazolopyridine is a potent class in 
heterocyclic compounds which possess a wide 
spectrum of biological activities2. The bromodomains 
of CBP/EP300 are targeted in transcriptional 
regulators factor in human cancer immunotherapy3. 
The BET family are inhibition of bromodomains is 
exposed to have probable therapeutic advantage in 
cancer, inflammation, immunology4. Acetyl Lysine 
modifications in proteins is recognition that 
Bromodomains are involved in transcriptional 
regulation. Highly discerning inhibitor of the CREB 
binding protein (CBP) bromodomain and its exploit in 
cell-based transcriptional application. For the gene 
regulation CBP and p300 (CREBBP or KAT3A and 
EP300 or KAT3B) are used two major HATs6. In Cell 
biology T cell regulation of the CREBBP/EP300 
bromodomains have a major role and T Cells are used 
in cancer immunotherapy7. Post translational change 
in the function of bromodomains in protein molecules 
in acetylated lysine on histones, important functions8. 
The CREBBP Bromodomain ligands with cation π 
interaction are useful tools9. Pyrazolopyridines are 
interrelated with DNA and inhibit growth of cancer 
cell lines10. For non-BET bromodomain have the 
proteins have been used in the HIV and cancer 
diseases chemical Probes potentially lead to drug 
discovery11. Bromodomains that have the domains are 
BCPs, HATs and HDAC are effectively used in 
cancer therapy12. BET bromodomain has reflective 
anticancer and anti-inflammatory in the chemical 
probes used in biological observed compounds in 
clinical trials13. The CREBBP bromodomain binds to 
KAc382 in human cancer with p53 and acetylation-
dependent and DNA damage14. The BET family has 
the schoffled bromodomain BRD2, BRD3, BRD4 are 
binding specificity very strong and prospective 
therapeutic benefit15. The CBP/p300 bromodomains 
are used in regulators of cell growth acetyl-lysine 
protein inhibitor16. The oncogenic fusion in leukemia 
is a MOZ acetyl transferees to detect CBP/p300 
domain17,18. The AML1-ETO fusion protein interacts 
with p300 and transcription regulates in AML1–ETO 
aim gene inhibitor of DNA binding19. Screening of a 
small molecular library identifies the compound 
interaction of p 53 and KAc382-CREBBP at 100 and 
50 μM respectively20. For the novel male 




contraceptives is a first bromodomain of BRDT-1 is 
for male germ cell differentiation used and c-Myc-
dependent cancers21. 
In BRD4 activation of the tumor in the micro level 
in vivo, the reduction of tumor growth and pulmonary 
of the metastasis in mice and human BRDs in 
chromatin biology and gene transcription22. Here we 
are report the development of a pyrazolopyridine 
based series of compounds, showing the silico 
discovery of CREB binding protein and bromodomain 
and efficacy towards antitumor activity (Figure 1). 
Molecular docking plays an important role of small 
molecule to their target protein in order to discover its 
affinity and activity its binding site23. Molecular 
dynamics simulations as tool as of medicinal 
chemistry has been successfully used for design of 
biologically active to identify antitumor activity, 
including inhibition and stability24. In this study 
microsecond molecular simulation is used to binding 
site of RVX-208 with bromodomain of BET 
proteins25. Molecular dynamics are ligand design 
focused on the potential molecule for the CBP 
bromodomain and high selectivity26. 
 
Results and Discussion 
In general, the yields of the synthesis were quite 
good and reasonable quantities of the materials were 
easily available. Although this general synthetic route 
was used for the synthesis of most of the analogues, 
other methods could be used for specific substitution 
patterns and will be given in the Experimental 
Section. The compounds were purified by normal 
synthetic medicinal chemistry means, usually column 
chromatography, and their structures were determined 
by high field NMR spectroscopy. The starting 
aldehyde, ketone required for further transformation 
were prepared by claisen-schmidt condensation. 
 
Synthesis of substituted chalcones 
A mixture of substituted aldehydes (0.02 mol ) and 
1-methyl-4-piperidone (0.01 mol) in the presence of 
10% NaOH along with 50 mL ethanol was prepared 
and the solution of reaction mixture was constant 
stirring for 15hrs at RT of stirring the solution was 
poured in to ice cubes to enhance the precipitation. 
The precipitate was then collected and washed with 
distilled water for draining excess sodium hydroxide 
from the product 3a1-10. The compound is purified and 
recrystallized with ethanol (Scheme I). 
 
Synthesis of substituted pyrazolo pyridine 
derivatives 
Equal moles of substituted chalcone and 
semicarbazide hydrochloride with 10% sodium 
hydroxide were refluxed at 80°C in a heating mantle 
for 6 hr produced, substituted pyrazolopyridine 4a1-7. 
All the compounds were purified by recrystallization 





For medicinal chemistry to discover the drug 
molecule to identify novel drug molecular docking 
technology. The molecular docking studies are to 
specify best ligand interaction and stable 
molecule27. To dock, 20 structures of ligands have 
been determined. Meanwhile, these ligands were 
used to conduct native docking to measure the 
 








docking conformations. Three different  
docking programs SP Glide, and XP Glide, Prime MM- 
GBSA were used for improving the accuracy of 
prediction. Then, Xscore followed by molecular 
docking was reliable and accurate for forecasting 
protein-ligand binding free energies (Table I). The 
docking results were evaluated by comparing values 
of score energy, SP Glide, XP Glide, and Binding 
energy. Through analysis of these results of docking 
simulations, most binding energy scores could 
accurately forecast the ligand activities. The lowest 
binding energy and the highest docking score 
demonstrated that these compounds (ligands) 
presented well favorable interactions. 
The docked ligands 4a, 5a, pyrazolo[4,3-
c]pyridine derivatives showed the best range of 






Table I — Glide Docking and binding energy scores 
Compd docking score Glide gscore Glide emodel XP GScore Glide energy Glide emodel 
5KTU -6.612 -6.612 -6.612 -6.612 -42.057 -59.809 
4a -6.237 -6.237 -6.237 -6.237 -35.312 -49.981 
5a -5.98 -5.98 -5.98 -5.98 -34.8 -49.39 
4d -5.572 -5.572 -5.572 -5.572 -31.043 -47.634 
4b -5.468 -5.468 -5.468 -5.468 -31.746 -40.129 
4f -4.96 -4.96 -4.96 -4.96 -26.952 -39.954 
4e -4.032 -4.032 -4.032 -4.032 -31.793 -45.413 
4c -3.946 -3.946 -3.946 -3.946 -34.717 -48.26 




The molecular docking results are recommended 
enhancement of the polar interaction Gln1113 side 
chain of the binding site (Figure 2). 
 
Molecular Dynamics Results 
Dynamics has become a useful tool for the 
prediction of usual motion of the molecular system. It 
explains protein structure and investigates the stability 
of the compounds. However, the large conformational 
space is more stable at lower simulated temperature28. 
The molecular dynamics simulations time scale is 10-
00 nsec with the protein and solvent system good29. It 
is a very useful tool in drug discovery to synthesize 
new targeted drug molecule interaction with ligand 
and protein molecule30.The molecular dynamics 
results are recommended enhancement of the polar 
interactions with the Asn1168 side chain of the 
binding site (Table II). In this case acetyl lysine 
ligand is hydrogen bond donor and acceptor for the 
amide side chain of the MD simulations with 
Asn1168, possible interaction (Figure 3). 
 
Protein-Ligand RMSD 
The binding mode of the CREBBP by interaction 
solvent MD simulations of the compound (Figure 4). 
If independent 1 μs MD runs are random velocities. 
The root-mean-square deviation in the time series 
(RMSD) of compound 4a shows that the binding 
mode and stability, although deviations of different 
magnitude are observed in the two MD runs 
(Figure 5). 
The additional support to docking and binding 
mode MD simulations is a key role. For the 
optimization process, the analysis of the interaction 





Figure 2 — Schematic representation of 4a in the binding pocket 1abd. The co-crystal structure of D and the CBP bromodomain 
(1.38 Å resolution; PDB code 5KTU) 
 
Table II — Interactions with Amino Acids for the Synthesized Compound against CREBBP bromodomain 
Compd Hydrogen 
Bonding 
Hydrophobic Interaction Water bridges 
4a Asn1168 Pro1110, Phe1111, Val 1115,  
Leu1120, Ile 1122, Tyr 1125, 
Ala 1164, Val 1174 
Gly1121,Tyr1167,Arg1169 
Asp1105,Arg 1112 
5KTU Asn1168 Leu1109, Phe1111,Ile1122, Val1175 Leu1120, Tyr1167, 
Val1174, Leu1109 
Gln1113,Tyr1125, Arg1112, Pro1110 





The biological studies are used to determine the  
anti-cancer activity. The human tumor cell lines were 
derived from nine different cancer types: breast, 
leukemia, melanoma, lung, colon, central nervous 
system, ovarian, renal, prostate cancers. Due to its 
high potency and selectivity, anticancer agents 
consisting of combined molecules have gained great 
interests. The in vitro anticancer activities against 
leukemia human cell lines for the synthesized 
compounds. In vitro antitumor assay of the new 
pyrazolopyridines toward leukemia Moreover, 
compound 4a IC50 = 62.5µg exhibited interesting 
 
Figure 5 — Structural stability and multiple binding modes of
Lead molecule protein-ligand RMSD of compound 4a 
 
Figure 6 — Structural stability and multiple binding modes of 
co-crystal protein-ligand RMSD with the CREBBP bromodomain 
in 50 ns 
 
 




Figure 4 — Co-Crystal 5KTU protein-ligand interaction CREBBP inhibitors 




efficacy on all tested compounds. The standard drug 
taken was Dox for leukemia cancer cell lines 
(Figure 7, Figure 8). 
 
Experimental Section 
Materials and methods 
The synthesized compounds were prepared by 
conventional heating and microwave irradiation 
technique. The structure of the prepared compounds was 
confirmed by different spectroscopic tools. All starting 
materials were purchased from Merck. The chemical 
structures of the obtained compounds were been 
confirmed by spectral analyses IR spectra were recorded 
as KBr pellets on a Perkin-Elmer instrument, 1H and 
13C NMR spectra were determined on a 400 MHz 
spectrometer and chemical shifts are expressed as δ 
(ppm) against TMS as internal reference. Mass spectra 
were recorded on 70 eV. Column chromatography was 
performed on Merck silica gel 60 (particle size 0.06 
mm-0.20 mm). The purity of the compounds was 
checked by thin-layer chromatography performed with 
Merck silica gel 60 F254 aluminium sheets. Spots were 
detected by their absorption under UV light. All 
compounds prepared in this paper are new and their 
structures confirmed from spectral data. 
 
Computational Studies 
Preparation of Ligands 
Structures of ligands sketched and saved in SDF 
format were imported via selecting files. The 
imported ligands 4a-g, 5a were set to minimize under 
force field OPLS3e. Minimization calculations can be 
performed on all structures of pyrazolo[4,3-c]pyridine 
derivatives. 
 
Preparation of Protein 
X-ray crystalline structure of protein 5KTU was 
imported from Protein Data Bank (PDB) to 
workspace, which further set to preprocess followed 
by review and modification to remove unwanted 
chains and residues, further refined under forcefield 




The compounds selected for molecular docking 
have some collective structural features. All the lead 
compounds showed good binding energy and 
exhibited interactions and better lower free energy 
values, indicating more thermodynamically favored 





Figure 7 — Pyrazolopyridine cores tested and found potential
against U937 Cell line Leukemia inhibition 




5KTU have been prepared by the protein preparation 
wizard in Schrödinger suite. Afterwards, receptor 
grids were generated before docking with the active 
site determined by the position of co crystal ligand. 
Crystal structures of 5KTU were imported into Glide, 
defined as the receptor structure and the location of 
active sites with a box. The PSLS3e force field was 
used for grid generation. The standard precision (SP) 
and the extra precision (XP) protocols were set for 
docking studies with crucial residues, in constrained 
binding to get accurate results. Binding affinity was 
retrieved running Prime MM-GBSA. All other 
parameters were maintained as default 
 
Molecular dynamics 
All computational works were performed using 
Schrödinger suite (Small-Molecule Drug Discovery 
Suite 2018-2, Schrödinger, LLC, New York, NY, 2018). 
 
Biological testing 
In vitro evaluation of the anticancer activity 
Primary anticancer assays were performed 
according to the NCI protocol as described elsewhere. 
The compounds were added at a single concentration 
and the cell cultures were incubated for 24h.The 
results for each compound are reported as the percent 
growth (GP %) of treated cells when compared to 
untreated control cells. The range of percent growth 
shows the lowest and the highest percent growth 
found among the cancer cell lines. 
 
Cell line and culture 
U937 cell line was obtained from NCCS, Pune. 
The cells were maintained in Minimal Essential 
Medium supplemented with 10% FBS, penicillin (100 
U/mL), and streptomycin (100 μg/mL) in a 
humidified atmosphere of 50 μg/mL CO2 at 37°C. 
 
In vitro assay for anticancer activity (MTT assay) 
(Mosmann, 1983) 
Cells (1 × 105/well) were plated in 24-well plates 
and incubated in 37°C with 5% CO2 condition. After 
the cell reaches the confluence, the various 
concentrations of the samples were added and 
incubated for 24hrs.100µl/well (5mg/mL) of 0.5% 3-
(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl--tetrazolium 
bromide (MTT) was added and incubated for 4 hours. 
After incubation, 1 mL of DMSO was added in all the 
wells.The absorbance at 570nm was measured with 
UV- Spectrophotometer using DMSO as the blank. 
Measurements were performed and the concentration 
required for a 50% inhibition (IC50) was determined 
graphically (Table III). The % cell viability was 
calculated using the following formula:  
 
% cell viability = A570 of treated cells / A570 of 
control cells × 100 
 
Graphs are plotted using the % of Cell Viability at 
Y-axis and concentration of the sample in X-axis. Cell 
control and sample control is included in each assay 





Equal moles of chalcone, semicarbazide were 
treated with 10% sodium hydroxide solution and 
refluxed for 6hr at 80°C mixture (3E,5E)- 3,5-
(trifluoromethyl)dibenzylidene -1-methylpiperidin-4-
one was treated with semicarbazide with 10% sodium 
hydroxide were refluxed at 80ºC in a heating mantel 
for 6hrs produced. Yield 74%. m.p.159°C. IR: 3550 
NH2, 3155 aromatic stretching, 1675 C=O, 1600 C=C, 
980 cm−1 C-F; 1H NMR: δ 2.09 (s,3H,CH3), 
6.12(s,2H,NH2), 7.24(m,Ar-H), 8.2 (s,1H, NH); 
13C NMR: δ 12.3,40.6, 60.9, 110.4,126.4, 130.7, 
135.2, 138.2, 147.7, 161.8; ESI-MS: m/z 480. 
 
(E)-7-Benzylidene-4,5,6,7-tetrahydro-5-methyl-3-
phenyl pyrazole[4,3-c]pyridine-2-carboxamide, 4b 
Yield: 88%. m.p.115-117ºC. IR: 1640 –CN,3300 –
NH2, 1555 C=C, 1690 C=O, Aromatic stretching 
2925 cm−1; 1H NMR: δ 2.27 (s,3H,CH3), 7.18-7.26 
(m,Aromatic H), 7.65 (NH); 13C NMR: δ 12.2, 40.3, 
95.4, 116.4, 126.4, 128.7, 135.2, 135.2, 138.2, 164.6; 
ESI-MS: m/z 344. 
 
(E)-7-(4-Diethylamino)benzylidene)-3-(4-diethy 
lamino) phenyl-4,5,6,7-tetrahydro-5-methyl pyra 
zole[4,3-c]pyridine-2-carboxamide, 4c 
Yield:84%. m.p.137°C. IR: 3458 NH2, 3165 aromatic 
stretching, 1685 C=O,1600 cm−1 C=C; 1H NMR: δ 2.07 
(s,3H,CH3), 3.05 (s,6H,N(CH3)2), 6.12 (s,2H,NH2), 
7.24 (m,Ar-H), 8.9 (s,1H, NH); 13C NMR: δ 12.6, 29.7, 
44.1, 45.6, 66.7, 110.5, 111.8, 122.5, 128.0, 130.7, 
132.2, 147.3, 190.0; ESI-MS: m/z 486. 
Table III — IC50of the tested compounds on leukemia cancer 
Compd IC50 (μg /mL) 
4a 62.5 
4b 31.2 
4e  31.2 
5b 62.5 
Standard-DOX 15.6 







Yield:72%. m.p.168°C. IR:3450 NH2, 3125 aromatic 
stretching, 1685 C=O, 1610 cm−1 C=C; 1H NMR: δ 2.15 
(s,3H, CH3), 6.18 (s, 2H, NH2), 7.14 (m, Ar-H), 8.7 (s, 
1H, NH); 13C NMR: δ 12.2 , 40.7, 60.7, 110.2, 126.4, 




methyl pyrazole[4,3-c]pyridine-2-carboxamide, 4e 
Yield:78%. m.p.159°C. IR: 3550 NH2, 3155 aromatic 
stretching, 1675 C=O, 1600 C=C, 980 cm−1 C-F. 
1H NMR: δ 2.09 (s, 3H, CH3), 6.12 (s, 2H, NH2), 7.12 
(m, Ar-H), 8.2 (s, 1H, NH); 13C NMR: δ 12.3, 40.6, 






Yield:74%. m.p.143°C. IR: 3430 NH2, 3115 
aromatic stretching, 1675 C=O,1600 cm−1 C=C; 
1H NMR: δ 2.06 (s, 3H, CH3), 6.12 (s, 2H, NH2), 7.14 
(m, Ar-H), 8.2 (s, 1H, NH); 13C NMR: δ 12.5, 40.5 , 
60.5, 76.8, 110.4, 126.4, 130.7, 135.2, 138.2, 150.5, 





Yield:74%. m.p.143°C. IR: 3560 NH2, 3135 
aromatic stretching, 1665 C=O, 1600 cm−1 C=C; 
1H NMR: δ 2.01 (s, 3H, CH3), 6.12 (s, 2H, NH2), 7.34 
(m, Ar-H), 8.4 (s, 1H, NH); 13C NMR: δ 12.5, 40.5, 
60.5, 76.8, 110.4, 126.4, 130.7, 135.2, 138.2,150.5, 
163.8; ESI-MS: m/z 404. 
 
(E)-7-Benzylidene-4,5,6,7-tetrahydro-5-methyl-3-
phenyl pyrazole[4,3-c]pyridine-2-carbothioamide, 5a 
Equal moles of mixture (3E,5E)- 3,5-dibenzylidene 
-1-methylpiperidin-4-one are treated with 
thiosemicarbazide with 10% sodium hydroxide were 
refluxed at 80°C in a heating mantle for 6hrs 
produced 5a. Yield: 88%. m.p.115-117°C. IR: 1640 –
CN,3300 –NH2, 1555 C=C, 2300 C=S, Aromatic 
stretching 2925 cm−1; 1H NMR: δ 2.05 (s, 3H, CH3), 
6.9 (S, α CH), 7.5 (d, β CH), 7.25-7.46 (m, Aromatic 
H), 8.0 (NH); 13C NMR: δ 12.2, 40.3, 95.4, 116.4, 
126.4, 128.7, 135.2, 135.2, 138.2, 176.6;  
ESI-MS: m/z 360. 
Conclusion 
Here we have outlined the identification of an 
inhibitor of the CBP/EP300 bromodomains that are 
potent biochemically and in cells and displays suitable 
metabolic stability for application as an in vivo probe. 
Compounds are belonging to this class of compounds 
exhibited moderate to potent anticancer activities in 
cell line tests. The synthesized compounds were 
prepared by conventional heating and microwave 
irradiation technique. Moreover, compound 4a 
exhibited interesting efficacy on all tested cell lines, 
whereas compound 4e showed good activity on MCF-
7 cells. 4a compounds are eco-friendly, safer and 
cheaper for the treatment of cancer. The intention of 
this study is focused to examine the comparative 
molecular docking studies on the target CREB-
binding protein which are responsible for cancer with 
the ligand of 4a-5j. The comparative docking studies 
were done by “Schrödinger Maestro 12.1”. 4a has a 
better binding score (−6.237 Kcal/mol) than the other 
standard drugs. The ligand 4e with the Glide score 
−5.572, shows the binding affinity with the amino 
acid (AA) residues GLU1113, PRO1110. These 
residues are acting as a conclusive pocket for the 
potential ligand. Hence it has been concluded that 4a 








Authors are thankful to Bioinformatics Infrastructure 
Facility Centre (BIFC), Queen Mary’s College, 
Chennai. I am also thankful to Dr. R. Girija Co-
ordinator, BIFC for their guidance and support. 
 
Reference 
1 Siegel R L, Miller K D & Jemal A, CA Cancer J Clin, 67 
(2017) 7. 
2 Bagi C M, J Musculoskelet Neuronal Interact, 2 (2002) 579. 
3 Terry D, Crawford F, Romero A & Lai K W, J Med Chem, 
59 (2016) 10549. 
4 Crawford T D, Tsui V & Flynn E M, J Med Chem, 1-40 (2016). 
5 Eugene L, Chekler P & Pellegrino J A, Chemistry & 
Biology, 22 (2015) 1. 
6 Delvecchio M, Gaucher J & Aguilar-Gurrier C, Nature 
Structural & Molecular Biology, 20 (2013) 1040. 
7 Ghosh S, Taylor A & Chin M, American Society for 
Biochemistry and Molecular Biology, 1-40 (2016). 
8 Romero F A, Taylor A M & Crawford T D, J Med Chem, 
59(4) (2016) 1271. 




9 Rooney T P C & Filippakopoulos P, Angew Chem Int Ed, 53 
(2014) 1. 
10 El-Gohary N S & Shaaban M I, European Journal of 
Medicinal Chemistry, 152 (2018) 126. 
11 Theodoulou N H & Tomkinson N C O, ChemMedChem, 11 
(2016) 477. 
12 Hohmann A F & Vakoc C R, Trends Genet, 30 (2014) 356. 
13 Schofield C J, Brennan P E, Knapp S & Conway S J, J Med 
Chem, 55 (2012) 9393. 
14 Mujtaba S, He Y, Zeng L, Yan S, Plotnikova O & 
Sachchidanand, Mol Cell, 13 (2004) 251. 
15 Muller S, Lingard H & Knapp S, Concepts Case Stud Chem 
Biol, 255-307 (2014). 
16 Picaud S, Fedorov O & Thanasopoulou A, Cancer Res, 
75(23) (2015) 5106. 
17 Katsumoto T, Yoshida N & Kitabayashi I, Cancer Sci, 99 
(2008) 1523. 
18 Zhang Y, Zeleznik-Le N, Emmanuel N, Jayathilaka N, Chen 
J & Strissel P, Genes Chromosomes Cancer, 41 (2004) 257. 
19 Zhao Y, Lu S, Wu L, Chai G, Wang H & Chen Y, Mol Cell 
Biol, 26 (2006) 2782. 
20 Xu M, Unzue A, Dong J & Spiliotopoulos D, J Med Chem, 
59(4) (2016) 1340. 
21 Ember S W J, Zhu J-Y & Olesen S H, ACS Chem Biol, 9 
(2014) 1160. 
22 Sanchez R & Zhou M-M, Curr Opin Drug Discov Dev, 12(5) 
(2009) 659. 
23 Eryanti Y, Zamri A & Nenifrimayanti, Orient J Chem, 33(5) 
(2017) 2164. 
24 Kaboli P J, Ismail P & Lin K-H, PLOS ONE, 3 (2018) 1. 
25 Wang Q, Li Y, Xu J, Wang Y & Elaine, Scientific Reports, 7 
(2017) 1. 
26 Batiste L, Unzue A & Dolbois A, ACS Cent Sci, 4(2) (2018) 
180. 
27 Lipinski C A, Lombardo F, Dominy B W & Feeney P J, Adv 
Drug Deliv Rev, 46 (2001) 3. 
28 Alim K, Lefranc B & Sopková-de Oliveira Santos J, J Med 
Chem, 3 (2018) 1. 
29 Pitman M R & Menz R I, Applied Mycology and 
Biotechnology, 6 (2006) 38. 
30 Sangshetti J N, Khan F A K & Qazi Y Q, Int J Pharm 
Pharmsci, 6(8) (2017) 217. 
 
 
 
 
 
 
